WO2022131717A1 - Nouveau peptide inhibant la protéine bet et composition le comprenant pour la prophylaxie et le traitement d'une maladie oculaire - Google Patents

Nouveau peptide inhibant la protéine bet et composition le comprenant pour la prophylaxie et le traitement d'une maladie oculaire Download PDF

Info

Publication number
WO2022131717A1
WO2022131717A1 PCT/KR2021/018859 KR2021018859W WO2022131717A1 WO 2022131717 A1 WO2022131717 A1 WO 2022131717A1 KR 2021018859 W KR2021018859 W KR 2021018859W WO 2022131717 A1 WO2022131717 A1 WO 2022131717A1
Authority
WO
WIPO (PCT)
Prior art keywords
retinal
retinopathy
macular degeneration
peptide
seq
Prior art date
Application number
PCT/KR2021/018859
Other languages
English (en)
Korean (ko)
Inventor
이인현
Original Assignee
주식회사 베노바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 베노바이오 filed Critical 주식회사 베노바이오
Publication of WO2022131717A1 publication Critical patent/WO2022131717A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Definitions

  • the present invention relates to a novel peptide exhibiting Bromodomain Extra-Terminal (BET) protein inhibitory ability and a composition for preventing, treating and improving ophthalmic diseases comprising the same as an active ingredient.
  • BET Bromodomain Extra-Terminal
  • the present invention inhibits retinal degeneration by inhibiting inflammatory response through epigenetic changes through a novel peptide BET inhibitor, thereby preventing various ophthalmic diseases such as diabetic retinopathy, wet and dry macular degeneration, glaucoma, and uveitis. And it may provide a pharmaceutical composition for treatment.
  • the eye is composed of the outer membrane, the media, the inner membrane, and the refractive medium.
  • the outer membrane is made up of the cornea, which is the anterior surface covering the black pupil, and the sclera following it.
  • the middle membrane is composed of the iris, ciliary body, and choroid.
  • the inner membrane consists of the retina.
  • the lens, vitreous, and aqueous humor are included in the refractive medium.
  • Functional impairment or loss of the eye is one of the factors that greatly reduce the quality of life, and it is important to maintain and protect the health of the eye due to various factors that can adversely affect it, such as aging, disease, and vision. is getting As ophthalmic diseases, there are various diseases such as retinal diseases including retinal degenerative diseases and glaucoma, cataracts, corneal epithelial disorders or corneal epithelial wounds.
  • Treatments for ophthalmic diseases currently under development are mainly steroids, matrix metalloproteinase (MMP) inhibitors, angiogenesis inhibitors, and antibodies to angiogenic growth factors.
  • MMP matrix metalloproteinase
  • the macula is a nervous tissue located in the center of the retina, and most of the photoreceptors are gathered here.
  • Macular degeneration is an eye disease that most often progresses with age. It is one of the difficult-to-treat eye diseases that causes blurred vision and distorted vision in the early stages of the onset, but later causes blindness.
  • Age-related macular degeneration is recently known as the most common cause of blindness in the elderly, and about 30 million people worldwide suffer from this disease, and about 500,000 patients suffer from this disease every year. is losing It is one of the three major causes of blindness along with glaucoma and diabetic retinopathy in Korea, and its prevalence is gradually increasing with an increase in the elderly population. The onset period also tends to decrease from the 60s to the middle-aged people in their 40s and 50s.
  • Age-related macular degeneration is largely classified into two types: exudative (wet) macular degeneration and atrophic (dry) macular degeneration. It is accompanied by fundus findings such as rupture of the pigment epithelium, and it is known that 70-90% of blindness due to age-related macular degeneration is due to exudative lesions.
  • the recently developed intravitreal anti-angiogenic growth factor antibody injection method a treatment for exudative age-related macular degeneration, improved patients' vision and improved the prognosis of the disease. Due to the inconvenience of having to undergo injection and the procedure that requires direct intravitreal drug delivery, complications such as cataract, endophthalmitis, vitreous hemorrhage, and retinal detachment increase. There is an urgent need to develop therapeutic agents that take gender into account.
  • glaucoma is a disease that causes the loss of ganglion cells in the retina and is closely related to retinal diseases.
  • Retinal degenerative disease is known as a disease in which vision is damaged due to degeneration of photoreceptors as it progresses by various environmental factors such as genetic or oxidative stress, and in most cases, from the early stage of the disease, peripheral They complain of a decrease in visual field, but central visual acuity is relatively well preserved.
  • glaucoma is a disease group consisting of various aspects showing various clinical and histopathological findings, and exhibits symptoms such as changes in the optic disc, damage to retinal ganglion cells, and visual field defects.
  • the retina is the innermost tissue of the eye belonging to the central nervous system.
  • Retinal degeneration is a pathological phenomenon that is accompanied by retinal diseases such as age-related macular degeneration and retinitis pigmentosa and leads to blindness due to the death of photoreceptors.
  • retinal diseases such as age-related macular degeneration and retinitis pigmentosa
  • retinal disease accompanied by retinal degeneration is an intractable disease.
  • Many diseases, including neurodegenerative diseases, accompany epigenetic changes, and recent attempts to prevent and treat diseases by controlling them have been made.
  • JQ a substance called JQ, known as one of a wide range of BET protein inhibitors, showed the potential to treat degenerative retinal diseases through microglial cell activation in a mouse model of retinitis pigmentosa (Zhao et al, 2017, Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration. Journal of Neuroinflammation (2017) 14:14, 1-15).
  • Non-Patent Document 0001 Zhao et al, 2017, Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration. Journal of Neuroinflammation (2017) 14:14, 1-15
  • the present invention provides a novel peptide having the ability to inhibit BET protein, and also uses the effect of the novel peptide to inhibit retinal degeneration such as reduction of inflammation through epigenetic changes, such as glaucoma, uveitis, wet and dry macular degeneration, age-related
  • An object of the present invention is to provide a composition for preventing or treating ophthalmic diseases such as macular degeneration.
  • the present invention provides a novel peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the present invention provides a pharmaceutical composition for preventing or treating ophthalmic diseases comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the ophthalmic diseases of the present invention include endophthalmitis, keratitis, conjunctivitis, keratoconjunctivitis, uveitis, blepharitis, scleritis, crizis, glaucoma, retinopathy, retinitis pigmentosa, retinal detachment, retinal pigment epithelial detachment, retinal tear, diabetic retinopathy, Retinopathy of prematurity, polypoidal choroidal vasculopathy, ischemic proliferative retinopathy, cone dystrophy, proliferative vitreoretinopathy, retinal artery occlusion, retinal vein occlusion, Levers's optic neuropathy, corneal renal neovascularization, retinal choroidal neovascularization, wet and dry macular degeneration, and age-related macular degeneration.
  • the present invention provides a food composition for preventing or improving ophthalmic diseases comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the present invention provides a feed composition for animals for preventing or improving ophthalmic diseases comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • novel peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 of the present invention alleviates the inflammatory response induced by retinal degeneration by epigenetic action that inhibits BET protein, thereby effectively inhibiting retinal degeneration.
  • This effect of inhibiting retinal degeneration can be applied to retinal degeneration and other central nervous system diseases through neuroinflammation control. Therefore, the novel peptide of the present invention can be usefully used for preventing or treating various eye diseases, such as glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration.
  • FIG. 6 to 9 show the results of analyzing the retinal sections of mice administered with the peptide (BBC0008) consisting of the amino acid sequence of SEQ ID NO: 2 by histological staining and immunohistochemical analysis.
  • FIGS. 10 and 11 show ERG analysis results for intraocular injection of Eylea, intraocular injection and intraperitoneal injection of the peptide (BBC0002) consisting of the amino acid sequence of SEQ ID NO: 1.
  • FIGS. 12 and 13 show ERG analysis results for intraocular injection of Eylea, intraocular injection and intraperitoneal injection of the peptide (BBC0008) consisting of the amino acid sequence of SEQ ID NO: 2.
  • the present invention provides a novel peptide (BBC0002) consisting of the amino acid sequence of SEQ ID NO: 1.
  • SEQ ID NO: 1 has the sequence of CSIECW, C is cysteine, S is serine, I is isoleucine, E is glutamate, and W is tryptophan.
  • the present invention provides a novel peptide (BBC0008) consisting of the amino acid sequence of SEQ ID NO: 2.
  • SEQ ID NO: 2 has a sequence of CSWWCW, C is cysteine, S is serine, and W is tryptophan.
  • the novel peptide of the present invention can prevent or treat macular degeneration by inhibiting angiogenesis in the eye, and the macular degeneration may be wet and dry macular degeneration and age-related macular degeneration, but is not limited thereto. It can also act on various eye diseases such as glaucoma and uveitis.
  • the present invention provides a composition for the treatment, prevention or improvement of an eye disease comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the eye diseases include glaucoma, uveitis, wet and dry macular degeneration, age-related macular degeneration, and the like.
  • the composition of the present invention may be a pharmaceutical composition for preventing or treating various eye diseases, such as glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration, including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 have.
  • the pharmaceutical composition is selected from the group consisting of suitable carriers, excipients, disintegrants, sweeteners, coating agents, swelling agents, lubricants, lubricants, flavoring agents, antioxidants, buffers, bacteriostats, diluents, dispersants, surfactants, binders and lubricants.
  • suitable carriers excipients, disintegrants, sweeteners, coating agents, swelling agents, lubricants, lubricants, flavoring agents, antioxidants, buffers, bacteriostats, diluents, dispersants, surfactants, binders and lubricants.
  • suitable carriers excipients, disintegrants, sweeteners, coating agents, swelling agents, lubricants, lubricants, flavoring agents, antioxidants, buffers, bacteriostats, diluents, dispersants, surfactants, binders and lubricants.
  • the preferred dosage of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or the composition comprising the peptide may vary depending on the subject's condition and weight, the type and degree of disease, drug form, administration route and period and may be appropriately selected by those skilled in the art.
  • the 'subject' may be a mammal including a human, but is not limited to these examples.
  • composition of the present invention provides a food composition for preventing or improving various eye diseases, such as glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration, including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. .
  • the food composition may be a health functional food, dairy product, fermented product or food additive.
  • the food composition includes various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids , a protective colloidal thickener, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like.
  • various nutrients vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids , a protective colloidal thickener, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like.
  • the health functional food refers to a food manufactured and processed using raw materials or ingredients useful for the human body, and "functionality" is useful for health purposes such as regulating nutrients or physiological action for the structure and function of the human body. It means taking it for the purpose of obtaining an effect.
  • composition of the present invention contains a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 for preventing or improving various eye diseases such as glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration. to provide.
  • the feed composition for animals can be ingested by all non-human animals, such as non-human primates, sheep, dogs, cattle, horses, and the like.
  • the inhibitory ability test for BRD4 (BD1+BD2) is as follows.
  • Each plate contained a negative control in which biotinylated acetyl-histone H4 peptide and GST-BRD4 (BD1 + BD2) were drained and replaced with assay buffer.
  • a negative control value was entered as a low reference value.
  • a positive control probe molecule I-BET762 with protein/peptide mixture was also pipetted. Determination of IC50 values was performed using GraphPad Prism 3.03 software (or an updated version thereof).
  • the peptide consisting of the amino acid sequence of SEQ ID NO: 1 of the present invention represents 56%
  • the peptide consisting of the amino acid sequence of SEQ ID NO: 2 is 47 %
  • mice 7-week-old male albino BALB/c mice were used. Three rats were randomly assigned to each test group, and the contrast was maintained at 12-hour intervals. After each mouse was dark-adapted for 24 h, the pupils were dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride eye drops (Santen, Osaka, Japan) 30 min before blue LED exposure. Unanesthetized mice were exposed to a blue LED (460 ⁇ 10 nm) of 2,000 lux for 2 hours in a cage with reflective interiors. The light intensity was measured using an LED photometer (model TM-201L, TENMARS Electronics, Taipei, Taiwan). After exposure to blue LEDs, they were placed in the dark for 24 hours and then the 12-hour light-dark cycle was resumed for 3 days.
  • an LED photometer model TM-201L, TENMARS Electronics, Taipei, Taiwan
  • test group was divided into an untreated control group (retinal degeneration untreated control group), a group administered with PBS to retinal degeneration mice, and a peptide (BBC0008) administration group (5 mg/kg) consisting of the amino acid sequence of SEQ ID NO: 2, 3 for each test group were randomly assigned.
  • Each sample was administered 1 hour after LED exposure, and the PBS-treated group and the peptide (BBC0008) administration group consisting of the amino acid sequence of SEQ ID NO: 2 were first injected into the abdominal cavity immediately before LED exposure, and the second injection was performed 3 days later. It was administered intraperitoneally.
  • Electroretinography ECG
  • Electroretinal angiography (ERG) recordings were performed by Kim et al. (Kim, G. H., Kim, H. I., Paik, S. S., Jung, S. W., Kang, S., and Kim, I. B. (2016). Functional and morphological evaluation of blue light-emitting diode. -induced retinal degeneration in mice, Graefes Arch. Clin. Exp. Ophthalmol. 254, 705-716) was followed.
  • mice were kept in a completely dark room for 16 h prior to ERG recording. All animals were intraperitoneally anesthetized with zolazepam (20 mg/kg) and xylazine (7.5 mg/kg). The cornea was coated with hydroxypropyl methylcellulose gel and covered with a gold ring contact electrode. A ground electrode and a reference electrode were placed subcutaneously on the tail and ears, respectively. Stimulation was a short white flash delivered through a Ganzfeld stimulator (UTAS-3000; LKC Technologies, Gaithersburg, MD, USA). The signal was amplified and filtered through a digital bandpass filter ranging from 5 to 300 Hz to generate a wave and b wave.
  • zolazepam 20 mg/kg
  • xylazine 7.5 mg/kg
  • the cornea was coated with hydroxypropyl methylcellulose gel and covered with a gold ring contact electrode.
  • a ground electrode and a reference electrode were placed subcutaneously on the tail and ears, respectively.
  • Stimulation was a
  • Scotopic ERG rod-mediated responses were obtained at increasing light intensities of 0.025 and 3.96 cd/s ⁇ m 2 .
  • Photopick, cone-mediated responses were obtained after 5 min light adaptation to background luminosity. Recordings were taken at a luminous intensity of 6.28 cd/s m 2 . Each recording was the average of three responses obtained within the 15 s interstimulation interval. The amplitude of the A-wave was measured from the baseline to the maximum a-wave peak, and the b-wave was measured from the maximum a-wave peak to the maximum b-wave peak.
  • FIGS. 1 to 5 The results of ERG analysis are shown in FIGS. 1 to 5 . 1 to 5, the peptide (BBC0008) administration group (5 mg/kg) consisting of the amino acid sequence of SEQ ID NO: 2 is significantly superior to both a-wave and b-wave compared to other administration groups wavelength (P ⁇ 0.05).
  • tissue staining method was performed as follows. After 3 days of blue LED exposure, the eyecup was removed and fixed in 4% paraformaldehyde for 2 h. After fixation, for frozen tissue specimens (TissueTek OCT compound; Sakura Finetek, Alphen aan den Rijn, The Netherlands), eye cups were washed with 0.1 M phosphate buffer (PB; pH 7.4), transferred to 30% sucrose, and infiltrated overnight.
  • PB phosphate buffer
  • Retinal sections were cut in the sagittal plane and stained with hematoxylin and eosin (H & E). Quantitative analysis was performed on the stained sections.
  • Outer nuclear layer (ONL) thickness was measured at 240 ⁇ m spacing (top to bottom) in vertical strips of the retina.
  • Muller glial cells express GFAP in response to retinal damage or stress. GFAP expression is initiated towards the ONL in the ganglion cell layer (GCL). It was confirmed that the peptide (BBC0008) administration group consisting of the amino acid sequence of SEQ ID NO: 2 had significantly less GFAP expression than the PBS administration group. Therefore, it can be seen that the peptide (BBC0008) treatment group consisting of the amino acid sequence of SEQ ID NO: 2 of the present invention significantly improves retinal damage.
  • microglia are mainly observed at the boundary of the outer nuclear plexus (OPL), inner nuclear layer (INL), and inner plexiform layer (IPL) in normal cells.
  • OPL outer nuclear plexus
  • the outer nuclear layer (ONL) is very thin in the degenerative cells in which the retinal degeneration has occurred, and microglia are widely distributed in the degenerating outer nuclear layer (OPL) and the subretinal space.
  • microglia are activated and migrated in response to retinal damage and inflammation.
  • the group administered with the peptide (BBC0008) consisting of the amino acid sequence of SEQ ID NO: 2 had significantly fewer IBA-1 labeled microglia in the outer nuclear layer (OPL) than the group administered with PBS.
  • Immunohistochemical analysis was performed as follows. After washing with 0.01 M PBS, retinal sections were pre-incubated in 10% normal donkey serum for 1 h at room temperature. The sections were then divided into a rabbit polyclonal anti-ionizable calcium binding adapter molecule 1 (Iba-1) antibody (1:1000; Wako Pure Chemical Industries, Osaka, Japan), a rabbit polyclonal anti-glial fibrotic acid protein (GFAP) antibody ( 1:1000; Chemicon, Temecula, CA, United States) was diluted in PBS at 4 °C for 1 day.
  • Iba-1 rabbit polyclonal anti-ionizable calcium binding adapter molecule 1
  • GFAP rabbit polyclonal anti-glial fibrotic acid protein
  • the peptide (BBC0008) administration group consisting of the amino acid sequence of SEQ ID NO: 2 was confirmed that Iba-1 (red) and GFAP (green) expression in the outer nuclear layer was significantly reduced than the PBS administration group.
  • Each test group was an untreated control group (retinal degeneration untreated control group), a group administered with Normal Saline (NS) to retinal degeneration mice, a group administered with Eylea IVT (administration dose 25 mg/kg), and a peptide consisting of the amino acid sequence of SEQ ID NO: 1 ( BBC0002) and the peptide (BBC0008) consisting of the amino acid sequence of SEQ ID NO: 2 were divided into an IVT administration group (administration dose 0.5 mg/kg) and an IP administration group (10 mg/kg), and three animals were randomly assigned to each test group.
  • Example 3 Each sample was administered 1 hour after the LED exposure, the IVT group was administered once by intravitreal injection, and the PBS treated group and the IP group were injected twice in the abdominal cavity immediately before exposure to the LED and 2 times after 3 days. It was administered intraperitoneally. After administration, the ERG was analyzed in the same manner as in Example 3, and the results are shown in FIGS. 10 to 13 .
  • the peptide (BBC0002) IP administration group (10 mg/kg) consisting of the amino acid sequence of SEQ ID NO: 1 had a-wave, b-wave compared with other administration groups including the Eylea IVT administration group All of them showed significantly superior wavelengths.
  • the peptide (BBC0002) IVT administration group (0.5 mg/kg) consisting of the amino acid sequence of SEQ ID NO: 1 was 20 times higher than that of the IP administration group (10 mg/kg) and the Eylia IVT administration group (administration dose 25 mg/kg) and It showed better wavelength at 50 times lower concentration.
  • the peptide (BBC0008) IVT administration group (0.5 mg/kg) consisting of the amino acid sequence of SEQ ID NO: 2 was 20 times higher than that of the IP administration group (10 mg/kg) and the Eylia IVT administration group (administration dose 25 mg/kg) and A better wavelength was exhibited at 50-fold lower concentrations.
  • the novel peptide of the present invention having excellent BET inhibitory ability exhibits excellent efficacy in the various biomarkers in the retinal degeneration-induced mouse model, thereby exhibiting an excellent retinal degeneration inhibitory effect, and the novel peptide is glaucoma, uveitis , wet and dry macular degeneration, age-related macular degeneration, etc. can be used as pharmaceuticals for the prevention and treatment of various eye diseases.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un nouveau peptide et une composition pharmaceutique comprenant, en tant que principe actif, une composition du peptide pour la prophylaxie et le traitement de diverses maladies oculaires, y compris le glaucome, l'uvéite, la dégénérescence maculaire humide et sèche, la dégénérescence maculaire liée à l'âge et analogues. Étant donné que le nouveau peptide selon la présente Invention inhibe la protéine BET pour améliorer l'inflammation provoquée par des lésions rétiniennes résultant de changements épigénétiques, les effets du peptide sur la prophylaxie et l'amélioration de diverses maladies oculaires provoquées par la dégénérescence rétinienne ont été confirmés. En conséquence, une composition comprenant le peptide en tant que principe actif peut être fournie sous la forme d'une composition pharmaceutique pour la prophylaxie et le traitement de diverses maladies oculaires, y compris le glaucome, l'uvéite, la dégénérescence maculaire humide et sèche, la dégénérescence maculaire liée à l'âge et analogues.
PCT/KR2021/018859 2020-12-15 2021-12-13 Nouveau peptide inhibant la protéine bet et composition le comprenant pour la prophylaxie et le traitement d'une maladie oculaire WO2022131717A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20200175308 2020-12-15
KR20200175306 2020-12-15
KR10-2020-0175306 2020-12-15
KR10-2020-0175308 2020-12-15

Publications (1)

Publication Number Publication Date
WO2022131717A1 true WO2022131717A1 (fr) 2022-06-23

Family

ID=82059311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/018859 WO2022131717A1 (fr) 2020-12-15 2021-12-13 Nouveau peptide inhibant la protéine bet et composition le comprenant pour la prophylaxie et le traitement d'une maladie oculaire

Country Status (2)

Country Link
KR (1) KR20220085726A (fr)
WO (1) WO2022131717A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150299201A1 (en) * 2012-09-28 2015-10-22 Bayer Pharma Aktiengesellschaft Bet protein-inhibiting 5-aryl triazole azepines
WO2018170464A1 (fr) * 2017-03-17 2018-09-20 The Johns Hopkins University Thérapie épigénétique ciblée contre l'élément de régulation distale d'expression du tgfb2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150299201A1 (en) * 2012-09-28 2015-10-22 Bayer Pharma Aktiengesellschaft Bet protein-inhibiting 5-aryl triazole azepines
WO2018170464A1 (fr) * 2017-03-17 2018-09-20 The Johns Hopkins University Thérapie épigénétique ciblée contre l'élément de régulation distale d'expression du tgfb2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN 5 June 2019 (2019-06-05), ANONYMOUS: "hypothetical protein AAS21_gp123 [Pantoea phage vB_PagS_AAS21]", XP055943052, retrieved from GENBANK Database accession no. QCW23861 *
LI JUN: "Epigenetic intervention with a BET inhibitor ameliorates acute retinal ganglion cell death in mice", MOLECULAR VISION, vol. 23, 1 January 2017 (2017-01-01), pages 149 - 159, XP055943089 *
W EICHENBAUM JOSEPH: "Bromodomain Inhibitors in Degenerative Eye Disease; An Alternative to VEGF Inhibitors in Macular Degeneration?", WORLD JOURNAL OF OPHTHALMOLOGY & VISION RESEARCH, vol. 3, no. 1, pages 1 - 4, XP055943084, DOI: 10.33552/WJOVR.2020.03.000553 *

Also Published As

Publication number Publication date
KR20220085726A (ko) 2022-06-22

Similar Documents

Publication Publication Date Title
Berson et al. Paraneoplastic night blindness with malignant melanoma
Wiechmann et al. Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues
Gao et al. Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1ΔE9 mice and its immunomodulatory mechanisms
Valiente-Soriano et al. Topical brimonidine or intravitreal BDNF, CNTF, or bFGF protect cones against phototoxicity
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
Cerri et al. Conjunctivally applied BDNF protects photoreceptors from light-induced damage
US9345749B2 (en) Method of treating intraoccular tissue pathologies with nerve growth factor
KR102331421B1 (ko) 녹내장의 치료
May et al. Choroidal ganglion cell plexus and retinal vasculature in monkeys with laser-induced glaucoma
Liu et al. A novel rat model of ocular hypertension by a single intracameral injection of cross‐linked hyaluronic acid hydrogel (Healaflow®)
WO2022131717A1 (fr) Nouveau peptide inhibant la protéine bet et composition le comprenant pour la prophylaxie et le traitement d'une maladie oculaire
JP2021512086A (ja) アルツハイマー病の予防又は治療方法
US9844556B2 (en) Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
He et al. Association of High-Mobility Group Box-1 with Inflammationrelated Cytokines in the Aqueous Humor with Acute Primary Angle-Closure Eyes
Chen et al. Interleukin‐17A modulates retinal inflammation by regulating microglial activation via the p38 MAPK pathway in experimental glaucoma neuropathy
US10435444B2 (en) Agent for prevention or treatement of corneal disorders
Rejdak et al. Changes of kynurenic acid content in the rat and chicken retina during ontogeny
WO2018212708A1 (fr) Traitement du glaucome
WO2024014792A1 (fr) Composition pharmaceutique pour traiter des maladies oculaires comprenant des exosomes dérivés d'organoïdes rétiniens
JP2020523416A (ja) 神経変性眼科学的病状の治療に使用する血清
RU2442582C2 (ru) Стимулятор образования нейритов
Kjellström et al. Retinal function in rabbits does not improve 4–5 months after terminating treatment with vigabatrin
Kwong et al. Novel Therapeutic Targets for Glaucoma: Disease Modification Treatment, Neuroprotection, and Neuroregeneration
JP2023553162A (ja) 眼疾患及び障害を処置するための化合物
Charish Targeting Neogenin as a Novel Therapeutic Approach for the Treatment of Retinal Degeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21907021

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21907021

Country of ref document: EP

Kind code of ref document: A1